M-Ghadanfar Consulting
Life Sciences
Independent Strategic Expertise for Global Life Science Leaders
I help biotech, pharma, and investors make smarter, faster, and safer decisions in drug development —
combining scientific rigor, clinical insight, and strategic clarity.
Mathieu Ghadanfar, MD, FESC, FAHA
President & Founder
🔐 Confidential 🧠 Independent 📊 Evidence-Driven ⚙️ Agility and Precision
Who I Help
I collaborate with leaders across the life science ecosystem — from emerging biotech ventures to global pharmaceutical organizations and investment firms — to transform scientific innovation into sustainable value.
Each audience faces distinct challenges, but the goal is the same: accelerate development, strengthen strategic clarity, and maximize value creation.
Biotech Founders —
-
The challenge: Early-stage biotech leaders often face the dual challenge of scientific depth and strategic scarcity. Turning a breakthrough into a credible development plan demands clinical, regulatory, and investor fluency — all under tight resource constraints.
-
How I help: I partner with founders to translate strong science into investable development programs. Together, we define a focused clinical and regulatory path, sharpen the value narrative for investors, and build the evidence base that attracts capital or partnerships.
-
Outcome: Accelerated clinical progress, disciplined decision-making, and a clear trajectory toward value creation or exit.
Pharma Executives —
-
The challenge: Established pharma organizations seek innovation without compromising scale, compliance, or alignment. Integrating external science and emerging technologies into large, matrixed systems can slow decision-making and dilute impact.
-
How I help: I work with senior leaders to streamline development portfolios, sharpen translational priorities, and bridge R&D with medical and commercial strategy.
-
Outcome: Faster advancement of promising assets, stronger cross-functional execution, and a culture of strategic clarity and accountability — where innovation translates efficiently into patient and business outcomes.
Investors —
-
The challenge: Investors operate in an environment of asymmetric information and scientific complexity. Assessing a company’s translational credibility or clinical feasibility requires more than due diligence checklists — it demands domain insight and strategic context.
-
How I help: I support investment teams by evaluating clinical and regulatory readiness, differentiating robust science from unscalable claims, and identifying inflection points that drive valuation.
-
Outcome: Enhanced capital efficiency, accelerated portfolio progress, and investment decisions grounded in real-world development potential and exit strategy.
About Mathieu Ghadanfar, MD, FESC, FAHA
Cardiologist & Vascular Disease Specialist I Biotech and pharma executive I Global strategic consultant in life sciences.
I founded M. Ghadanfar Consulting in 2020 to unite three decades of experience spanning academic cardiology, clinical development, medical affairs, and regulatory strategy — expertise shaped through senior global leadership roles at Pfizer, Novartis, and pioneering biotech ventures.
My mission is to deliver the strategic discipline, analytical depth, and scientific rigor of large organizations — combined with the agility, independence, and confidentiality of a boutique practice.
I help innovators, executives, and investors navigate complex translational, clinical, and regulatory decisions with clarity and conviction.
Alongside my advisory work, I remain actively engaged with the scientific community through international cardiovascular societies and peer-reviewed publications, fostering continuous dialogue between clinical science, therapeutic innovation, and strategic execution.
🔬 Strategic Leadership & Scientific Innovation in Life Sciences
With over 25 years of experience in the biopharmaceutical industry, I specialize in scientific innovation, clinical development, regulatory strategy, and medical affairs. I have successfully led high-performing teams, spearheaded critical drug development programs, secured key regulatory approvals, and launched high-impact therapies across multiple therapeutic areas. My expertise allows me to provide holistic scientific and strategic leadership to advance life sciences innovations from discovery to commercialization.
🚀 Founder & President | M-Ghadanfar Consulting Life Sciences
As the Founder and President of M-Ghadanfar Consulting, I provide strategic advisory services to biotech startups, pharmaceutical companies, and investors, helping them navigate complex regulatory landscapes, optimize clinical development strategies, and accelerate market access. My deep industry knowledge and global perspective enable me to drive biopharma innovation, business growth, and strategic decision-making. I am also committed to mentorship and leadership development, empowering teams and individuals to excel in the evolving life sciences ecosystem.
💡 Biopharma Executive | Former Pfizer & Novartis Leader
With a distinguished career at Pfizer and Novartis, I have led large-scale drug development programs, late-stage clinical trials, and regulatory submissions, culminating in successful product approvals and global launches. My expertise in Clinical Development and Global Medical Affairs has played a pivotal role in shaping innovative therapies and delivering transformative healthcare solutions.
🎓 Distinguished Academic & Global Healthcare Expert
Holding an MD and a Board certificate in Cardiology and Vascular Medicine from Paris, complemented by diplomas in Echocardiography, Pharmacology, and Clinical Trials Methodology, I bring a strong scientific and clinical foundation to my work. As a French citizen based in Switzerland, I have led multicultural teams across Europe and the US, fostering global collaborations and advancing medical innovation in diverse regulatory environments.
🔗 Professional Affiliations, Recognitions and Publication
-
Global Fellow in Medicines Development (GFMD) – IFAPP
-
Fellow of the European Society of Cardiology (ESC)
-
Fellow of the American Heart Association (AHA)
-
Gold Member of the European Society of Heart Failure
-
Member of the French Society of Cardiology
-
Member of the Hypertension and Stroke Councils of ESC
-
Full list of Publication: https://pubmed.ncbi.nlm.nih.gov/?term=ghadanfar+m
Strategic Advisory for Biotech, Pharma &
Life Sciences Growth Strategic Partner
🔬 Clinical Development Strategy
I provide independent guidance on the strategic design and execution of clinical programs — from proof-of-concept through pivotal trials.
Services include:
• Clinical development plan design and optimization
• Feasibility assessment and risk–benefit modeling
• Interim or fractional clinical leadership and coaching
📊 Medical Affairs Excellence
Medical Affairs is the strategic bridge between science and market access. I help organizations structure and optimize these functions to deliver measurable impact.
Services include:
• Setting up and scaling medical affairs teams to drive biopharma
• Scientific communication and KOL engagement frameworks
• Evidence generation and publication planning
• Launch readiness and post-approval support
💡 Regulatory & Scientific Advisory
Decisions succeed when regulatory strategy is integrated early. I provide senior-level advisory across therapeutic and global regulatory contexts.
Services include:
• Global regulatory landscape assessment (EMA, FDA, others)
• Gap analysis and mitigation strategy
• Preparation for agency interactions and advisory boards
🚀 Investment & Due Diligence
For venture investors, boards, and M&A teams, I provide confidential, scientifically grounded evaluations of assets and portfolios.
Services include:
• Scientific and regulatory due diligence
• Independent review of clinical programs and datasets
• Risk and probability-of-success assessment
• Portfolio prioritization and strategic recommendations
🏥 Shaping the Future of Healthcare with Digital & Policy Innovation
-
Integrating new technologies into healthcare projects, including telehealth, remote care, and AI-driven medical solutions.
-
Advising on external affairs, medical policy, and regulatory trends shaping the future of biotech and pharma.
Let’s Shape the Future of Life Sciences — Together
At M. Ghadanfar Consulting, I partner with biotech innovators, pharmaceutical leaders, and life-science investors to transform science into strategic value.
From clinical development and medical affairs to regulatory strategy and investment guidance, I deliver tailored, evidence-driven solutions that accelerate progress and build lasting impact.
